On 16 September 2026, HANSOH PHARMA (03692.HK) announced that HS-20197 for injection, a Class 1 innovative drug independently developed by the Group, obtained a drug clinical trial approval notice issued by the National Medical Products Administration on 11 September 2026, for the conduct of clinical trials in "advanced solid tumours".
On 16 September 2026, SSY GROUP (02005.HK) announced that the Group's ziprasidone mesylate has been approved by the National Medical Products Administration of the PRC for registration as an active pharmaceutical ingredient for use in marketed formulations, mainly for the treatment of acute agitation in patients with schizophrenia.
On 16 September 2026, PCCW (00008.HK), HKT-SS (06823.HK) and HKT Trust jointly announced that the disposal of the target interest was completed on 16 September 2026, with the total consideration of USD 209,452,500 paid in full in cash to the HKT group.
On 16 September 2026, PSBC (01658.HK) announced that the qualification of Mr. Sun Maozhu as an independent non-executive director has been approved by the National Financial Regulatory Administration, with effect from his taking office on 11 September 2026 for a term of three years, and that Mr. Zhong Ruiming ceased to serve as an independent non-executive director and on the relevant Board committees due to the expiry of his term of office.
On 16 September 2026, XIN YUAN ENT (01748.HK) announced that Mr. Liu Dunyu, an executive director, has been appointed as an authorised representative of the Company under Rule 3.05 of the Listing Rules to fill the temporary vacancy arising from the termination of Mr. Chen Jiagan's service as an executive director, and that trading in the Company's shares will remain suspended.
On 16 September 2026, HUAJIN INTL (02738.HK) announced that Haiyi Limited, the controlling shareholder, conducted an off-market placing through a placing agent on 14 September 2026, selling an aggregate of 174,000,000 shares of the Company to multiple placees, representing approximately 29.00% of the total issued share capital as at the date of the announcement, at an average price of approximately HKD 0.038 per share.
On 16 September 2026, 160 HEALTH (02656.HK) announced that Shenzhen 160 Network Technology Co., Ltd., an indirect wholly-owned subsidiary of the Group, entered into a strategic co-operation framework agreement with a limited liability company registered in Shenzhen, the PRC, under which the co-operating party has preliminarily agreed to procure a certain scale of enterprise-level AI computing infrastructure with an estimated total co-operation amount of about RMB 650 million.
On 16 September 2026, Zhejiang Leapmotor Technology Co., Ltd. (09863.HK) announced that it has received the CSRC approval dated 10 September 2026 (Zheng Jian Xu Ke [2026] No. 2434) for the registration of the issue of shares, under which the CSRC has approved the issue of new Domestic Shares to FAW Equity and Jinyi High-tech under the Domestic Shares Subscriptions; the approval is valid for twelve months from the date of approval of registration.
On 16 September 2026, China Cinda Asset Management Co., Ltd. (01359.HK) announced that it intends to redeem all of its Offshore Preference Shares (stock code 04621) on 3 November 2026 at an aggregate redemption price of USD 1.7748 billion, comprising USD 1.7 billion of liquidation preference and USD 74.8 million of declared but unpaid dividends; following the redemption there will be no Offshore Preference Shares in issue and the Company will apply to withdraw the listing.
on September 16, 2026, the three major Hong Kong indices opened higher and moved in a choppy range, with the Hang Seng Index up 0.19%, the Hang Seng TECH Index up 0.79%, and the Hang Seng China Enterprises Index up 0.02%. The Hang Seng Index's total market turnover was 181.1 billion HKD, Southbound funds saw a net inflow of 2.099 billion HKD.
on 16 September 2026, robot-themed shares traded in a range, while HUAYAN ROBOTICS (01021.HK) strengthened. As of 15:15, the company quoted HKD 11.110, up 12.00%.
on 16 September 2026, AI chip stocks strengthened, with SMIC (00981.HK) strengthening as well. As of 13:36, the company quoted HKD 63.200, up 4.03%.
on 16 September 2026, humanoid robot stocks traded actively while UBTECH ROBOTICS (09880.HK) strengthened. As of 13:25, the company quoted HKD 77.550, up 1.11%.
On 16 September 2026, Nissin Foods Company Limited (01475.HK) announced that, with effect from 15 September 2026, Mr. Keiji Iwakiri has been appointed as a member of the Company's senior management; he joined the Group in April 2019 and is currently deputy managing director of Nissin Foods (H.K.) Company Limited and managing director of Kagome Nissin Foods (H.K.) Company Limited, overseeing sales functions in Hong Kong.
On 16 September 2026, YESTAR HEALTH (02393.HK) published its interim report, with revenue down 17.6% to RMB 661.6 million, gross profit up 8.3% and a loss of RMB 479,000, with no interim dividend declared.
On 16 September 2026, SBP GROUP (01177.HK) announced that the NDA for TQH2722 injection (an IL-4Rα monoclonal antibody), a National Class 1 innovative drug independently developed by its subsidiary Chia Tai Tianqing, has been accepted for review by the CDE, for moderate-to-severe atopic dermatitis in adults.
